This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): transdermal exenatide, PassPort Basal Insulin
Description: The exenatide transdermal patch is an investigational product designed to be applied once per day toprovide sustained levels of exenatide (Byetta) for people with type 2 diabetes.
Altea, Eli Lilly and Amylin
In April 2009, Altea Therapeutics announced that it entered into anagreement with Eli Lilly and Company and Amylin Pharmaceuticals to develop and commercialize its exenatide transdermalpatch.
Under the terms of the agreement, Altea has granted Lilly and Amylin exclusiveworldwide rights to develop and commercialize transdermal exenatide utilizing the Altea'sproprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all productdevelopment, manufacturing, and commercialization activities for the product. In addition, AlteaTherapeutics will receive from Lilly and Amylin an upfront license payment and may receive clinical,regulatory and sales milestones of up to $46 million, and royalties on future product sales.
Eli Lilly and Amylin
In November 2011, Amylin and Eli Lilly announced an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies. As part of the...See full deal structure in Biomedtracker
Partners: Eli Lilly & Company Nitto Denko Corporation Bristol-Myers Squibb Company
Exenatide Patch News
Additional information available to subscribers only: